BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Blue Ash Therapeutics, Forest Laboratories deal

Blue Ash granted Forest exclusive, worldwide rights to antiarrhythmic candidate azimilide. Last year, Blue Ash licensed the potassium channel blocker from Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland), which acquired the...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >